

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 June 2002 (27.06.2002)

PCT

(10) International Publication Number  
WO 02/49590 A2

(51) International Patent Classification<sup>7</sup>: A61K 7/32

Port Sunlight, Quarry Road East, Bebington, Wirral,  
Merseyside CH63 3JW (GB).

(21) International Application Number: PCT/EP01/13253

(74) Agents: ELLIOTT, Peter, William et al.; Unilever PLC,  
Patent Dept., Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).

(22) International Filing Date:  
14 November 2001 (14.11.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,  
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0031264.5 21 December 2000 (21.12.2000) GB

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(71) Applicant (for AE, AG, AU, BB, BZ, CA, CY, GB, GD, GH,  
GM, IE, IL, KE, LC, LK, LS, MN, MW, NZ, SD, SG, SL, SZ,  
TT, TZ, UG, ZA, ZW only): UNILEVER PLC [GB/GB];  
Unilever House, Blackfriars, London EC4P 4BQ (GB).

Published:


- without international search report and to be republished upon receipt of that report
- entirely in electronic form (except for this front page) and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for AL, AM, AT, AZ, BA, BE, BF, BG, BJ, BR,  
BY, CF, CG, CH, CI, CM, CN, CO, CR, CU, CZ, DE, DK,  
DM, DZ, EC, EE, ES, FI, FR, GA, GE, GN, GQ, GR, GW,  
HR, HU, ID, IS, IT, JP, KG, KP, KR, KZ, LR, LT, LU, LV,  
MA, MC, MD, MG, MK, ML, MR, MX, MZ, NE, NL, NO,  
PH, PL, PT, RO, RU, SE, SI, SK, SN, TD, TG, TI, TM, TR,  
UA, UZ, VN, YU only): UNILEVER N.V. [NL/NL]; Weena  
455, NL-3013 AL Rotterdam (NL).

(71) Applicant (for IN only): HINDUSTAN LEVER LIMITED [IN/IN]; Hindustan Lever House, 165/166 Backbay  
Reclamation, Maharashtra, 400 020 Mumbai (IN).

(72) Inventors: SMITH, Ian, Karl; Unilever Research Port  
Sunlight, Quarry Road East, Bebington, Wirral, Mersey-  
side CH63 3JW (GB). RIELEY, Hugh; Unilever Research



WO 02/49590 A2

(54) Title: ANTIPERSPIRANT PRODUCTS

(57) Abstract: Antiperspirant products and methods for achieving antiperspirancy utilising compositions comprising an antiperspirant salt and a water soluble polymer, characterised in that: i) the polymer comprises Brønsted acid groups and acts as a co-gellant for the antiperspirant salt when mixed therewith in the presence of water; and ii) the polymer is physically separate from antiperspirant salt prior to application.

BEST AVAILABLE COPY

- 1 -

ANTIPERSPIRANT PRODUCTS

FIELD OF INVENTION

5 This invention relates to the field of antiperspirant deodorant products. More specifically, it relates to antiperspirant deodorant products comprising an antiperspirant salt and a water soluble polymer that comprises Brønsted acid groups and acts as a co-gellant for  
10 the antiperspirant salt when mixed therewith in the presence of water.

BACKGROUND OF INVENTION

15 Cosmetic antiperspirant and deodorant products are known. Typical antiperspirant products comprise topically acceptable compositions containing a metal salt, such as an astringent aluminium or aluminium/zirconium salt, in combination with a cosmetically suitable vehicle. Typical  
20 deodorant products comprise topically acceptable compositions containing one or more agents that mask or inhibit the formation of unpleasant body odours; antimicrobial agents are widely used for this purpose. Such cosmetic antiperspirant and deodorant products may be  
25 available in a variety of product forms, for example as sticks, creams, soft-solids, roll-on lotions, aerosols, pump sprays and squeeze sprays.

Whilst such compositions provide a degree of antiperspirancy  
30 and malodour reduction, there can be problems associated with their use and there is always a desire for improved performance. A problem encountered by some people, is that the application of high levels of astringent antiperspirant salts leads to skin irritation. Others find similar  
35 problems with certain antimicrobial agents. Other problems

- 2 -

include formulation difficulties with the high levels of active ingredients sometimes required. It has long been desirable to achieve excellent protection from body malodour without the use of high concentrations of conventional 5 antiperspirant or deodorant agents. This could lead to antiperspirant and deodorant products being cheaper, easier to formulate (by virtue of the reduced amount of antiperspirant active used), or generally having improved sensory properties. Other benefits of requiring lesser 10 amounts of conventional antiperspirant or deodorant agents include the reduced concentration on the body of such 'foreign' agents and the reduced impact on the environment, in terms of chemical usage and processing.

15 The above problems have been addressed in a number of ways in the past, examples including the use of certain polymers as antiperspirant actives. WO 93/24105 (Tranner) describes the use of particular water-insoluble film-forming polymers, with conventional antiperspirant salts being non-essential, 20 optional components in the compositions of the invention. The examples given that include antiperspirant salt also comprise co-polymers of octylacrylamide/acrylates or PVP/acrylates. No reference is made to interactions between the antiperspirant salts and the polymers. References to 25 film-forming polymers are also made in JP 2290810 (Nakagawa et al) and WO 95/27473 (Causton and Baines). An alternative approach is described in EP 701812 (Abrutyn et al), where porous polymer beads are claimed to be capable of absorbing sweat components.

30 Polymers have also been used to enhance the performance of antiperspirant salts by increasing the residual amount of antiperspirant salt on the skin. Thus, EP 222580 (Klein and Sykes) describes the use of dimethyldiallyl ammonium 35 chloride (DMQAAC) polymers for this purpose.

- 3 -

The use of DMQAAC/acrylic acid-type co-polymers to thicken personal care products is described in EP 266,111 (Boothe et al) and EP 478,327 (Melby and Boothe). The latter of these 5 patents discusses the thickening of metal-containing aqueous compositions by said co-polymers.

Aqueous compositions comprising an acrylic acid containing polymer and an antiperspirant salt are described in WO 98/50005 and WO 98/48768 (Ron et al). In these patents, 10 the proposed invention relates to the reverse thermal viscosifying benefit of the polymer.

US 5,194,262 and US 5,271,932 (Goldberg et al) describe antiperspirant compositions containing microcapsules comprising an antiperspirant salt encapsulated within a water-soluble shell possessing a bioadhesive. Polyacrylic acid is disclosed as a possible component of both the water-soluble shell and the bioadhesive. 15

20 **SUMMARY OF INVENTION**

We have discovered that the performance of conventional antiperspirant salts can be improved by the addition of polymers that are capable of interacting with the 25 antiperspirant salts on contact with the skin.

Thus, according to a first aspect of the present invention, there is provided an antiperspirant product comprising an antiperspirant salt and a water soluble polymer, 30 characterised in that:

- (i) the polymer comprises Brønsted acid groups and acts as a co-gellant for the antiperspirant salt when mixed therewith in the presence of water; and

- 4 -

(ii) the polymer is physically separate from antiperspirant salt prior to application.

According to a second aspect of the present invention, there  
5 is provided a cosmetic method of achieving an antiperspirancy and/or deodorancy benefit, said method comprising the topical application to the human body of an antiperspirant product as defined in the first aspect of the invention.

10

According to a related aspect of the invention, there is provided a cosmetic method of achieving an antiperspirancy and/or deodorancy benefit, said method comprising bringing together on the surface of the human body an antiperspirant  
15 salt and a water soluble polymer comprising Brønsted acid groups which, in the presence of water, acts as a co-gellant for the antiperspirant salt.

According to a third aspect of the present invention, there  
20 is provided a method for the manufacture of an antiperspirant composition, comprising the mixing, in a fluid carrier material, of an antiperspirant salt and a water soluble polymer, wherein said polymer comprises Brønsted acid groups and acts as a co-gellant for the  
25 antiperspirant salt, when mixed therewith in the presence of water, and wherein the polymer is physically separate from antiperspirant salt in the composition.

DETAILED DESCRIPTION OF THE INVENTION

30

The interaction between the antiperspirant (AP) salt and the polymer, on application to the human body, is an essential factor in this invention. The interaction between the components is chemical in nature and results in a thickened  
35 or gelled state of matter. It is desirable that the

- 5 -

interaction between the components does not occur significantly before they are brought into contact with the human body. Such premature interaction can result in numerous problems including unwanted thickening of the 5 product, poor dispensing, poor sensory properties, and poor antiperspirancy and/or deodorancy performance. Avoidance of premature interaction involves keeping the polymer physically separate from the AP salt. This may be achieved by co-application of the components from independent 10 compositions; such co-application being done concurrently or consecutively, with either the AP salt or the polymer being applied first.

Alternatively, a composition comprising a non-interacting 15 mixture of the AP salt and the polymer may be employed. Such compositions comprise the polymer physically separate from the AP salt. Non-interacting mixtures of this kind are ones where intimate contact between the AP salt and the polymer is not possible. Mixtures of this kind include co- 20 dispersions of the AP salt and the polymer in a non-solvent carrier material. Examples of mixtures that do not meet this criterion include a true solution comprising both AP salt and the polymer and mixtures comprising AP salt encapsulated by the polymer.

25 In a particular aspect of the present invention, compositions comprising a non-interacting mixture of the AP salt and the polymer are essentially non-aqueous compositions. Essentially non-aqueous compositions comprise 30 less than 10% by weight of water, preferably less than 5% by weight of water, and most preferably less than 1% by weight of water, excluding any water of hydration associated with the AP salt. In addition to being essentially non-aqueous, many compositions comprising both the AP salt and the 35 polymer comprise less than 20% or even less than 10% by

- 6 -

weight of polar organic solvents, for example C<sub>2</sub> to C<sub>4</sub> alcohols (monohydric or polyhydric), like ethanol.

Polymers

5

The polymers of the present invention are water soluble and comprise Brønsted acid groups. In addition, the polymers act as co-gellants for the AP salt when mixed therewith in the presence of water, for example water in human sweat, at 10 a temperature of 37°C or less. The co-gelation results in a thickened state of matter - that is to say, the three component system (polymer, AP salt, water) has a higher viscosity than that of an aqueous solution of either the polymer or AP salt alone. Without wishing to be bound by 15 theory, it is believed that the co-gelation involves chemical interaction between electronegative groups on the polymer and polyvalent hydrated metal cations deriving from the antiperspirant salt.

20 A simple test that may be used to determine whether or not a polymer is able to act as a co-gellant is given as Example 1. The test consists essentially of mixing aqueous solutions of the polymer and the AP salt and looking for an increase in viscosity.

25

The water solubility of the polymers used in the present invention, when measured at 37°C, is preferably 10g/l or greater, more preferably 50g/l or greater, and most preferably 100g/l or greater. It is required that the 30 polymers form true solutions, rather than dispersions, in water; such true solutions typically having an absorbance of less than 0.2, preferably less than 0.1 (for a 1 cm pathlength at 600 nm) measured using a Pharmacia Biotech Ultrospec 200 Spectrophotometer or similar instrument. It

- 7 -

is also desirable that the polymer is water soluble at pH 7; the attainment of said pH generally requiring a certain amount of neutralisation of the Brønsted acid groups present.

5

The Brønsted acid groups in the polymer may be present in their protonated form or may be present in their neutralised form as salt groups. Both partially-neutralised and fully-neutralised acidic polymers may be employed as co-gellants

10 in the present invention. Suitable Brønsted acid groups include carboxylic acid groups, sulphonic acid groups, and phosphonic acid groups. Carboxylic acid groups are particularly preferred. Brønsted acid groups are preferably present at a concentration of greater than 0.1 mmole per 15 gram of polymer, more preferably at a concentration of greater than 1.0 mmole per gram of polymer, and most preferably at a concentration of greater than 3.0 mmole per gram of polymer. These preferred levels relate to monobasic Brønsted acid groups and should be reduced *pro rata* for 20 polybasic Brønsted acid groups. Latent Brønsted acid groups, such as anhydrides or other groups that generate Brønsted acid groups on addition to water, may also be present.

25

Preferred polymers are organic polymers, in particular, organic polymers possessing only limited positive charge - for example, organic polymers having less than 50 mole %, preferably less than 25 mole %, of positively-charged monomer units. Especially preferred organic polymers are 30 nonionic and anionic polymers. Typical polymers possess carbon backbones, optionally interrupted by ester or amide links.

- 8 -

The acid value of a polymer is a widely used means of characterisation. Acid values generally express the acidity of a polymer in terms of the number of milligrams of potassium hydroxide base required to fully neutralise one 5 gram of the polymer. Thus, the unit of measurement can be abbreviated to mg KOH/g.

Many of the polymers of the present invention have acid values greater than 160. Preferred polymers have acid 10 values greater than 320 or even greater than 450. Particularly preferred polymers have acid values greater than 580. These acid values are based on the polymer in its fully protonated state; that is to say, the actual in-use extent of neutralisation of the polymer is ignored in 15 respect of the 'acid value'. Acid values may be measured experimentally or may be estimated theoretically. When using the latter method, acid anhydride groups present in a polymer should be counted as two acid groups, such anhydrides generally being hydrolysed to di-acids by 20 potassium hydroxide.

The preferred carboxylic acid groups may be introduced into the polymer by inclusion of monomers such as acrylic acid, methacrylic acid, maleic acid, itaconic acid, crotonic acid, 25 maleic anhydride, or itaconyl anhydride in the polymer. When the only source of Brønsted acid groups are anhydride monomers, it is required that the anhydride groups are at least partially hydrolysed prior to use of the polymer. Polymers comprising a mixture of any of the above acid 30 and/or anhydride monomers may also be advantageously employed. Particularly preferred polymers are those derived, at least in part, from maleic acid and/or maleic anhydride monomers.

- 9 -

It is sometimes desirable to include other monomers in the polymer. Suitable monomers include methyl vinyl ether, C<sub>1</sub>-C<sub>8</sub> alkyl acrylates and methacrylates, vinyl acetate, ethylene, and propylene. The inclusion of such monomers may aid 5 polymer synthesis, ease handling and/or formulation of the polymer, and may improve the performance of the polymer as a co-gellant.

The molecular weight of the polymer is preferably in the 10 range of 500 to 5,000,000, in particular 10,000 to 3,000,000 and especially 100,000 to 2,500,000. Selection of an appropriate molecular weight for the polymer may lead to benefits in terms of ease of formulation, product aesthetics (particularly product feel), and product performance.

15 The polymer is preferably incorporated into a composition in an amount of from 0.5% to 20% by weight, more preferably from 1% to 15% by weight, and most preferably from 2% to 12% by weight of said composition, excluding any volatile 20 propellant present.

In certain aspects of the present invention, the polymer is used in particulate form. When used in such form, the 25 polymer particles generally have sizes between 0.1 and 200  $\mu\text{m}$ , preferably with a mean particle size of from 3 to 50  $\mu\text{m}$ . When the antiperspirant is also used in particulate form, it is further preferred that the polymer be of similar particle size to the AP (vide infra).

30 The mean particle sizes referred to in this specification are volume means, as typically determined by light scattering techniques.

- 10 -

Antiperspirant Salts

Antiperspirant salts for use herein are often selected from astringent salts including, in particular, aluminium and

5 mixed aluminium/zirconium salts, including both inorganic salts, salts with organic anions, and complexes. Preferred astringent salts are aluminium and aluminium/zirconium halides and halohydrate salts, such as chlorohydrates.

10 Aluminium halohydrates are usually defined by the general formula  $Al_2(OH)_xQy \cdot wH_2O$  in which Q represents chlorine, bromine or iodine, x is variable from 2 to 5 and  $x + y = 6$  while  $wH_2O$  represents a variable amount of hydration. Especially effective aluminium halohydrate salts, known as

15 activated aluminium chlorohydrates, are described in EP006,739 (Unilever PLC and NV). Some activated salts do not retain their enhanced activity in the presence of water but are useful in substantially anhydrous formulations, i.e. formulations that do not contain a distinct aqueous phase.

20 Zirconium salts are usually defined by the general formula  $ZrO(OH)_{2-x}Q_x \cdot wH_2O$  in which Q represents chlorine, bromine or iodine; x is from about 1 to 2; w is from about 1 to 7; and x and w may both have non-integer values. Preferred are

25 zirconyl oxyhalides, zirconium hydroxyhalides, and combinations thereof. Nonlimiting examples of zirconium salts and processes for making them are described in Belgian Patent 825,146, Schmitz, issued August 4, 1975 and U.S. Patent 4,223,010 (Rubino).

30 The above aluminium and aluminium/zirconium salts may have coordinated and/or bound water in various quantities and/or may be present as polymeric species, mixtures or complexes.

- 11 -

Suitable aluminium-zirconium complexes often comprise a compound with a carboxylate group, for example an amino acid. Examples of suitable amino acids include tryptophan,  $\beta$ -phenylalanine, valine, methionine,  $\beta$ -alanine and, most 5 preferably, glycine.

It is highly desirable to employ complexes of a combination of aluminium halohydrates and zirconium chlorohydrates together with amino acids such as glycine, which are 10 disclosed in US 3,792,068 (Procter and Gamble Co.). Certain of those Al/Zr complexes are commonly called ZAG in the literature. ZAG actives generally contain aluminium, zirconium and chloride with an Al/Zr ratio in a range from 2 to 10, especially 2 to 6, an Al/Cl ratio from 2.1 to 0.9 and 15 a variable amount of glycine. Actives of this preferred type are available from Westwood, from Summit and from Reheis.

Other actives that may be utilised include astringent 20 titanium salts, for example those described in GB 2,299,506.

Antiperspirant salts are preferably incorporated into a composition in an amount of from 0.5-60%, particularly from 5 to 30% or 40% and especially from 5 or 10% to 30 or 35% of 25 the weight of the composition.

The proportion of solid AP salt in a composition normally 30 includes the weight of any water of hydration and any complexing agent that may also be present in the solid active. However, when the active salt is in solution, its weight excludes any water present.

The weight ratio of the AP salt to the polymer is preferably 35 25:1 or less, 1:10 or greater, particularly between 25:1 and 1:10, and especially between 10:1 and 1:5.

- 12 -

Frequently the AP salt may be present in a composition taking the form of a suspension in which the AP salt in particulate form is suspended in a water-immiscible liquid carrier. In such compositions, the particle size of the AP 5 salts often falls within the range of 0.1 to 200  $\mu\text{m}$  with a mean particle size often from 3 to 20  $\mu\text{m}$ . Both larger and smaller mean particle sizes can also be contemplated such as from 20 to 50  $\mu\text{m}$  or 0.1 to 3  $\mu\text{m}$ .

10 Optional Additional Components

A carrier material for the antiperspirant salt and/or the polymer is a highly desirable additional component of the products of the invention. Compositions preferably comprise 15 carrier material at a level of from 30% to 98%, or more preferably from 60% to 97% of the weight of the composition, excluding any volatile propellant present.

The carrier material may be hydrophobic or hydrophilic, 20 solid or liquid. Preferred carrier materials are hydrophobic. It is highly preferred that the solid or liquid carrier material is fluid at the temperatures typically used to make the product form in question. Hydrophobic liquid carrier materials particularly suitable 25 for use are liquid silicones, that is to say, liquid polyorganosiloxanes. Such materials may be cyclic or linear, examples include Dow Corning silicone fluids 344, 345, 244, 245, 246, 556, and the 200 series; Union Carbide Corporation Silicones 7207 and 7158; and General Electric 30 silicone SF1202. Alternatively, non-silicone hydrophobic liquids may be used. Such materials include mineral oils, hydrogenated polyisobutene, polydecene, paraffins, isoparaffins of at least 10 carbon atoms, and aliphatic or aromatic ester oils (e.g. isopropyl myristate, lauryl

- 13 -

myristate, isopropyl palmitate, diisopropyl sebacate, diisopropyl adipate, or C<sub>8</sub> to C<sub>18</sub> alkyl benzoates).

Hydrophilic liquid carrier materials that may be used 5 include water and polar organic solvents. When water is used as a carrier material for the polymer and/or the antiperspirant salt, it is strongly preferred that the polymer and the antiperspirant salt are applied from independent compositions. This ensures that premature 10 interaction does not occur between the components (vide supra). Polar organic solvents that may be employed include C<sub>1</sub>-C<sub>4</sub> monohydric alcohols, for example ethanol and isopropanol, and polyols, for example propylene glycol, dipropylene glycol, glycerol, polyethylene glycol, and C<sub>2</sub>-C<sub>8</sub> 15 1,2-alkanediols like 1,2-hexanediol.

An additional component that can sometimes augment deodorancy performance is an organic anti-microbial agent. Most of the classes of agents commonly used in the art can 20 be incorporated into products of the invention. Levels of incorporation are preferably from 0.01% to 3%, more preferably from 0.03% to 0.5%. Preferred organic anti-microbial agents are those that are more efficacious than simple alcohols such as ethanol. The preferred organic 25 anti-microbials are also bactericides, for example quaternary ammonium compounds, like cetyltrimethylammonium salts; chlorhexidine and salts thereof; and diglycerol monocaprate, diglycerol monolaurate, glycerol monolaurate, and similar materials, as described in "Deodorant 30 Ingredients", S.A.Makin and M.R.Lowry, in "Antiperspirants and Deodorants", Ed. K. Laden (1999, Marcel Dekker, New York). More preferred anti-microbials are polyhexamethylene biguanide salts (also known as polyaminopropyl biguanide

- 14 -

salts), an example being Cosmocil CQ available from Zeneca PLC, preferably used at up to 1% and more preferably at 0.03% to 0.3% by weight; 2',4,4'-trichloro,2-hydroxy-diphenyl ether (triclosan), preferably used at up to 1% by weight of the composition and more preferably at 0.05-0.3%; and 3,7,11-trimethyldodeca-2,6,10-trienol (farnesol), preferably used at up to 1% by weight of the composition and more preferably at up to 0.5%.

10 Structurants and emulsifiers are further additional components that are highly desirable in certain product forms. Structurants, when employed, are preferably present at from 1% to 30% by weight of a composition, whilst emulsifiers are preferably present at from 0.1% to 10% by weight of a composition. In roll-on compositions, such materials help control the rate at which product is dispensed by the roll ball. In stick compositions, such materials can form gels or solids from solutions or suspensions. Suitable structurants for use in such compositions include cellulosic thickeners such as hydroxypropyl cellulose and hydroxyethyl cellulose, fibre-forming structurants such as 12-hydroxystearic acid, esters of 12-hydroxystearic acid, amides of 12-hydroxystearic acid, stearic acid, behenic acid and di- and tri-glycerides thereof, N-lauroyl-glutamic acid dibutyl amide, 2-dodecyl-N,N'-dibutyl-succinamide, and dibenzylidene sorbitol. Partially or fully esterified disaccharides, for example cellobiose octanoates, may also be used, as may structurants like dextrin palmitate. Sterols (e.g.  $\beta$ -sitosterol) and sterol esters (e.g. oryzanol) are also suitable for use, when used in combination. Emulsion pump sprays, roll-ons, creams, and gel compositions can be formed using a range of oils, waxes, and emulsifiers. Suitable emulsifiers include steareth-2, steareth-20, steareth-21, ceteareth-20, glyceryl stearate, cetyl alcohol, cetearyl alcohol, PEG-20 stearate,

- 15 -

and dimethicone copolyol. Suspension aerosols, roll-ons, sticks, and creams require structurants to slow sedimentation (in fluid compositions) and to give the desired product consistency to non-fluid compositions.

5 Suitable structurants include sodium stearate, stearyl alcohol, cetyl alcohol, hydrogenated castor oil, beeswax, synthetic waxes, microcrystalline wax, paraffin waxes, candelilla wax, dibutyl lauroyl glutamide, alkyl silicone waxes, quaternium-18 bentonite, quaternium-18 hectorite, 10 silica, and propylene carbonate. Some of the above materials also function as suspending agents in certain compositions.

Further emulsifiers desirable in certain compositions of the 15 invention are perfume solubilisers and wash-off agents. Examples of the former include PEG-hydrogenated castor oil, available from BASF in the Cremaphor RH and CO ranges, preferably present at up to 1.5% by weight, more preferably 0.3 to 0.7% by weight. Examples of the latter include 20 poly(oxyethylene) ethers.

Certain sensory modifiers are further desirable components in the compositions of the invention. Such materials are 25 preferably used at a level of up to 20% by weight of the composition. Emollients, humectants, volatile oils, non-volatile oils, and particulate solids that impart lubricity are all suitable classes of sensory modifiers. Examples of such materials include cyclomethicone, dimethicone, dimethiconol, isopropyl myristate, isopropyl palmitate, 30 talc, finely-divided silica (e.g. Aerosil 200), particulate polyethylene (e.g. Acumist B18), polysaccharides, corn starch, C12-C15 alcohol benzoate, PPG-3 myristyl ether, octyl dodecanol, C7-C14 isoparaffins, di-isopropyl adipate, isosorbide laurate, PPG-14 butyl ether, glycerol, 35 hydrogenated polyisobutene, polydecene, titanium dioxide,

- 16 -

phenyl trimethicone, dioctyl adipate, and hexamethyl disiloxane.

5 Fragrance is also a desirable additional component in the compositions of the invention. Suitable materials include conventional perfumes, such as perfume oils and also include so-called deo-perfumes, as described in EP 545,556 and other publications. Levels of incorporation are preferably up to 10 4% by weight, particularly from 0.1% to 2% by weight, and especially from 0.7% to 1.7% by weight.

15 It should be noted that certain components of compositions perform more than one function. Such components are particularly preferred additional ingredients, their use often saving both money and formulation space. Examples of such components include the many components that can act as both structurants and sensory modifiers, for example silica.

20 Further additional components that may also be included are colourants and preservatives at a conventional level, for example C<sub>1</sub>-C<sub>3</sub> alkyl parabens.

#### Product Forms

25 The products of the invention may comprise compositions taking any form. When the product comprises more than one composition, it is preferred that the compositions take the same form. Example compositions include wax-based sticks, soap-based sticks, compressed powder sticks, roll-on 30 suspensions or solutions, emulsions, gels, creams, squeeze sprays, pump sprays, and aerosols. Each product form contains its own selection of additional components, some essential and some optional. The types of components typical for each of the above product forms may be

- 17 -

incorporated in the corresponding compositions of the invention.

Roll-on compositions of the invention preferably have a low  
5 level of non-volatile emollient present, for example isopropyl myristate or propylene glycol at 0.2-2% by weight. Antiperspirant sticks have cyclomethicone as a preferred carrier fluid. Also preferably present are one or more ethers or esters previously mentioned as sensory modifiers; 10 these materials can serve to mask deposits. Wash-off agents are also desirable in such compositions.

Aerosol Compositions

15 Aerosol compositions of the invention are a particularly preferred product form. Preferably the propellant is the major component in such compositions, comprising from 30 to 99 parts by weight, more preferably from 50 to 95 parts by weight.

20 The propellant is normally selected from liquified hydrocarbons or halogenated hydrocarbon gases (particularly fluorinated hydrocarbons such as 1,1-difluoroethane and/or 1-trifluoro-2-fluoroethane) that have a boiling point of 25 below 10°C and especially those with a boiling point below 0°C. It is especially preferred to employ liquified hydrocarbon gases, and especially C<sub>3</sub> to C<sub>6</sub> hydrocarbons, including propane, isopropane, butane, isobutane, pentane and isopentane and mixtures of two or more thereof.

30 Preferred propellants are isobutane, isobutane/isopropane, isobutane/propane and mixtures of isopropane, isobutane and butane.

- 18 -

Other propellants that can be contemplated include alkyl ethers, such as dimethyl ether or compressed non-reactive gasses such as air, nitrogen or carbon dioxide.

5 The base composition, which is mixed with the propellant, may comprise any of the following components as preferred additional ingredients: a carrier material (fluid), a fragrance, an emollient (e.g. isopropyl myristate or propylene glycol) or an anticlogging agent (in order to  
10 prevent or minimise the occurrence of solid occlusions in the spray nozzle). Further components may be added to mask powdery deposits, for example non-volatile oils, long chain alcohols (e.g. octyl dodecanol), ethers (e.g. PPG-14 butyl ether), or dimethicone fluids.

15 An aerosol composition is usually filled into an aerosol canister that is capable of withstanding pressures generated by the formulation, employing conventional filling apparatus and conditions. The canister can conveniently be a  
20 commercially available metal canister fitted with a dip tube, valve and spray nozzle through which the formulation is dispensed.

Methods of Manufacture

25 The details of the relevant methods of manufacture depend upon the product form concerned. For a product that is a composition comprising a non-interacting mixture of the AP salt and the polymer, the basic method comprises the  
30 addition of the AP salt and the polymer to a fluid carrier material, keeping the AP salt and the polymer physically separate. In this context, a fluid carrier material is one capable of flow at the temperature used during the manufacture of the product. It is essential that the mixing

- 19 -

is done in such a way as to prevent chemical interaction between the AP salt and the polymer. In a particularly preferred method, an essentially anhydrous carrier fluid is employed. It is further preferred that the AP salt and 5 polymer added to the anhydrous carrier fluid are present in particulate form.

EXAMPLES

10 Example 1: Co-gellant Test for Polymer

An aqueous solution of the polymer is prepared under conditions sufficient to fully hydrolyse any acid anhydride groups present to a concentration of 1.9% w/w. Said 15 solution is mixed with an aqueous solution of antiperspirant salt (50% w/w) in amounts sufficient to give a molar ratio of Brønsted acid group to antiperspirant metal ion of 1:1. If the viscosity of the resulting solution is greater than that of both of the starting solutions, then the polymer is 20 a co-gellant for the antiperspirant.

In a particular example, 0.42g of a 50% w/w solution of aluminium chlorohydrate was mixed with 9.97g of a 1.9% solution of Gantrez S-95 (see note to Table 1) to give a 25 molarity of 0.2M for both the aluminium ions and the Brønsted acid groups present. A gelled state of matter resulted from the mixing of the two free-flowing solutions.

- 20 -

Examples 2 to 6: Antiperspirancy Test

The following protocol was used to measure the sweat weight reduction (that is to say, the antiperspirancy benefit)  
5 resulting from use of the compositions given in Table 1.

The performance of each antiperspirant test product was compared to that of a non-antiperspirant control product on a panel typically consisting of 30 or more women. Before  
10 the test, the panellists were required to complete a "wash-out period" of approximately three weeks (17 days minimum). During the wash-out period, the panellists were forbidden from using any deodorant or antiperspirant product, other than a non-antiperspirant deodorant product given to them by  
15 the test operators.

After the wash-out period, the test operators applied the antiperspirant test product (0.30g) to one axilla and the non- antiperspirant control product (0.30g) to the other  
20 axilla of each panellist. This was done once each day for three days. After the third application, panellists were requested not to wash under their arms for the following 24 hours.

25 24 hours after the third and final product application, the panellists were induced to sweat in a hot-room at 40°C ( $\pm 2^\circ\text{C}$ ) and 40% ( $\pm 5\%$ ) relative humidity, for 40 minutes. After this period, the panellists left the hot-room and their axillae were carefully wiped dry. Pre-weighed cotton pads were then  
30 applied to each axilla of each panellist and the panellists re-entered the hot-room for a further 20 minutes. Following

- 21 -

this period, the pads were removed and re-weighed, enabling the weight of sweat generated to be calculated.

The sweat weight reduction (SWR) for each panellist was  
5 calculated as a percentage (% SWR) and the mean % SWR and  
95% confidence limits were calculated according to the  
method described by Murphy and Levine in "Analysis of  
Antiperspirant Efficacy Results", *J. Soc. Cosmetic Chemists*,  
1991(May), 42, 167-197.

10

Table 1 gives the mean % SWR and 95% confidence limits resulting from treatment with the indicated compositions.

- 22 -

Table 1

The compositional details given in the Tables are weight percentages and that letters designate comparative examples.

5

Example:	2	A	3	4	5	6	B	C
ACH <sup>1</sup>	11	11	0	0	0	0	0	0
AACH <sup>2</sup>	0	0	11	11	11	11	11	0
Gantrez AN-119 <sup>3</sup>	11	0	11	5.5	0	0	0	22
Gantrez S-95 <sup>4</sup>	0	0	0	0	11	0	0	0
PAA <sup>5</sup>	0	0	0	0	0	5.5	0	0
Bentone 38V <sup>6</sup>	3	3	3	3	3	3	3	3
Ethanol	1	1	1	1	1	0	1	1
Propylene carbonate	1	1	1	1	1	1	1	1
DC 245 <sup>7</sup>	73	84	73	78.5	73	79.5	84	73
% SWR:	48	34	51	51	50	49	35	0
95% limits	38-56	20-45	40-60	43-58	40-58	42-55	22-46	-13-11

1. Aluminium chlorohydrate, Microdry Super Ultra Fine, ex Reheis.
- 10 2. Activated aluminium chlorohydrate, type A296, ex Guilini.

- 23 -

3. Partially hydrolysed co-polymer of maleic anhydride and methyl vinyl ether (monobasic Brønsted acid group concentration: 3.4 mmole/g; acid value: 695; MW: ca. 216,000), ex International Speciality Products Inc. 5 (ISP).
4. Co-polymer of maleic acid and methyl vinyl ether (acid value: 592; MW: ca. 216,000), ex ISP.
5. Poly(acrylic acid), molecular weight about 450,000, ex Polysciences, Inc.
- 10 6. Quaternium-18 hectorite, ex Rheox.
7. D5 cyclomethicone fluid, ex Dow Corning.

The above roll-on antiperspirant compositions were prepared in the following manner. To a mixture of the propylene 15 carbonate, DC 245, and ethanol when present, was slowly added Bentone 38V, with stirring until homogeneous. The antiperspirant salt and the polymer were then slowly added and stirring was continued until a smooth, homogeneous suspension was formed.

20 The results in Table 1 illustrate the enhanced antiperspirancy performance of an ACH roll-on composition comprising partially hydrolysed Gantrez AN 119 (Example 2 vs. Example A) and the enhanced antiperspirancy performance 25 of AACH roll-on compositions comprising partially hydrolysed Gantrez AN 119 (Examples 3 and 4), Gantrez S-95 (Example 5), or poly(acrylic acid) (Example 5) in comparison with compositions containing no co-gellant polymer (Example B) or no antiperspirant salt (Example C).

30

- 24 -

Example 7: Further Antiperspirancy Test

A modification of the protocol described above was used to measure the sweat weight reduction resulting from use of the 5 compositions given in Table 2. The modified protocol differed in using male panellists instead of female; self-application of the test/control products; and hot-room entry 8 to 10 hours after the third and final product application. The compositions were prepared in a similar manner to those 10 of Table 1.

Table 2

Example:	7	D	E
AACH <sup>1</sup>	11	11	22
Gantrez AN-139 <sup>2</sup>	5.5	0	0
Bentone 38V	3	3	3
Ethanol	1	1	1
Propylene carbonate	1	1	1
DC 245	78.5	84	73
% SWR:	56	35	55
95% limits	44-66	22-44	44-64

15 1. As previously described (Table 1).  
 2. Partially hydrolysed co-polymer of maleic anhydride and methyl vinyl ether (acid value: 696; MW: ca. 1,080,000), ex ISP.

- 25 -

These results illustrate the enhanced antiperspirancy performance of a roll-on composition comprising Gantrez AN-139 (partially hydrolysed), when compared with comparative Example D. Comparison with comparative Example E 5 illustrates that the same antiperspirancy performance can be achieved using less antiperspirant salt, when compositions according to the invention are employed.

Further Roll-on Compositions

10

The compositions of Table 3 were prepared in a similar manner to those of Tables 1 and 2. All gave a satisfactory antiperspirancy benefit.

15 Table 3

Components as previously described.

Example:	8	9	10	11	12	13
AACH	5.5	3.2	2.2	16.5	18.8	19.8
Gantrez AN-119	16.5	18.8	19.8	5.5	3.2	2.2
Bentone 38V	3	3	3	3	3	3
Ethanol	1	1	1	1	1	1
Propylene carbonate	1	1	1	1	1	1
DC 245	73	73	73	73	83	73

20 Further Roll-on Compositions

The compositions of Table 4 were prepared in a similar manner to those of Tables 1, 2 and 3. All gave a satisfactory antiperspirancy benefit.

- 26 -

Table 4

Example:	14	15	16	17	18
AACH <sup>1</sup>	0	11	0	0	11
AZAG <sup>2</sup>	11	0	11	11	0
Gantrez AN-119 <sup>3</sup>	11	0	0	0	0
Gantrez AN-139 <sup>4</sup>	0	0	5.5	0	0
Gantrez AN-169 <sup>5</sup>	0	5.5	0	5.5	0
Poly(itaconic acid) <sup>6</sup>	0	0	0	0	5.5
Bentone 38V	3	3	3	3	3
Ethanol	1	1	1	1	0
Propylene carbonate	1	1	1	1	1
DC 245	73	78.5	78.5	78.5	79.5

1. As previously described.

5 2. Aluminium zirconium tetrachlorohydrex gly., Q5-7167, ex  
Summit.

3. As previously described.

4. As previously described.

5. Partially hydrolysed co-polymer of maleic anhydride and  
10 methyl vinyl ether (acid value: 695; MW: ca.  
1,980,000), ex ISP.

6. Ex Polysciences, Inc.

Soft Solid Compositions

15

The soft solid antiperspirant compositions of Table 5 were prepared in the following manner. The Finsolv-TN was heated to about 115°C and the GP-1 was added, with stirring until the GP-1 had dissolved. The mixture was then cooled to about 90°C and the dextrin palmitate was added, again with

- 27 -

stirring until dissolved. The mixture was then cooled to about 75-80°C and the AACH and AN-119 were added. Stirring was re-commenced until a homogeneous mixture was obtained. The mixture was then cooled to about 70°C and transferred to 5 an appropriate dispenser.

After cooling to ambient temperature, both products were assessed as previously described and were found to give a satisfactory antiperspirancy benefit.

10

Table 5

Example:	19	20
AACH <sup>1</sup>	12.75	25.5
Gantrez AN-119 <sup>2</sup>	12.75	12.75
GP-1 <sup>3</sup>	1	1
Dextrin palmitate	5	5
Finsolv-TN <sup>4</sup>	68.5	55.75

1. Activated aluminium chlorohydrate, A-418, ex Summit.  
15 2. As previously described.  
3. N-lauroyl-L-glutamic acid di-n-butylamide, ex  
Ajinomoto.  
4. C12-15 alkyl benzoate, ex Finetex.

20 Aerosol Compositions

The aerosol antiperspirant compositions of Table 6 were prepared and packaged in the following manner. The DC245 and the Bentone 38V were stirred together until a

homogeneous mixture was obtained. The fragrance material was then added with stirring. Stirring was then stopped whilst the AACH and AN-119 were added. Stirring was recommenced and continued until a homogeneous mixture was obtained. The resulting mixture was transferred into a conventional aluminium deodorant can, having valve access, and the CAP 40 liquefied volatile propellant was introduced into the can from a propellant 'transfer can', via the valve, using a polyethylene transfer device. Finally, the can was fitted with a suitable actuator to enable effective spray application of the product.

Table 6

Example	21	22	23
AACH <sup>1</sup>	8	9	4
Gantrez AN-119 <sup>2</sup>	2	1	1
Fragrance	0.65	0.65	0.3
DC245	14.25	14.25	7.1
CAP 40 <sup>3</sup>	75.1	75.1	87.6

15

1. Activated aluminium chlorohydrate, type A296, ex Guilini.
2. As previously described.
3. Propellant, proprietary mix of butane, isobutane and propane, ex Calor.

20

All the products were assessed as previously described and were found to give a satisfactory antiperspirancy benefit.

- 29 -

Stick Compositions

The stick compositions of Table 7 were prepared in the following manner. The stearyl alcohol, PEG distearate, 5 Castorwax MP80, and DC245 were heated to about 90°C, with stirring until a homogeneous mixture was obtained. The talc was then added, and mixed in, followed by the AZAG and the AN-119. Stirring was re-commenced and continued for a further 5 minutes to give a homogeneous mixture. Finally, 10 the fragrance material was added and mixed in and the composition was transferred to a suitable dispenser to cool and solidify.

Table 7

Example	24	25	26
AZAG <sup>1</sup>	24	12	24
AN-119 <sup>2</sup>	12	12	6
Fragrance	1	1	1
Castorwax MP80 <sup>3</sup>	4	4	4
Stearyl alcohol <sup>4</sup>	14	14	14
PEG distearate <sup>5</sup>	1	1	1
Talc <sup>6</sup>	3.2	3.2	3.2
DC245	to 100	to 100	to 100

15

1. Aluminium zirconium tetrachlorohydrex gly., Q5-7167, ex Summit.
2. As previously described.
3. Hydrogenated castor wax, ex Aston Chemicals.
- 20 4. Lanette 18, ex Henkel.
5. Estol EO4 DS 3724, ex Unichema.
6. Superfino talc, ex Cyprus Minerals.

- 30 -

CLAIMS

1. An antiperspirant product comprising an antiperspirant salt and a water soluble polymer, characterised in that:
  - (i) the polymer comprises Brønsted acid groups and acts as a co-gellant for the antiperspirant salt when mixed therewith in the presence of water; and
  - (ii) the polymer is physically separate from antiperspirant salt prior to application.
2. An antiperspirant product according to claim 1, characterised in that the polymer is an organic polymer having less than 50 mole-% of positively-charged monomer units.
3. An antiperspirant product according to claim 1 or claim 2, characterised in that the polymer is an organic polymer possessing a carbon backbone, optionally interrupted by ester or amide groups.
4. An antiperspirant product according to claim 2 or 3, characterised in that the polymer is nonionic or anionic.
5. An antiperspirant product according to any of the preceding claims, characterised in that the polymer has an acid value of greater than 160.
6. An antiperspirant product according to any of the preceding claims, characterised in that polymer comprises carboxylic acid groups.

35

- 31 -

7. An antiperspirant product according to claim 6, characterised in that the polymer is derived, at least in part, from maleic acid or maleic anhydride monomer units.
- 5 8. An antiperspirant product according to any of the preceding claims, characterised by comprising a composition comprising a carrier material.
- 10 9. An antiperspirant product according to claim 8, characterised in that the carrier material is a hydrophobic liquid.
- 15 10. An antiperspirant product according to any of the preceding claims, characterised by comprising an aerosol composition comprising a volatile propellant.
11. An antiperspirant product according to any of claims 1 to 9, characterised by comprising a stick composition comprising a structurant.
- 20 12. An antiperspirant product according to any of claims 1 to 9, characterised by comprising a cream composition comprising a structurant and/or an emulsifier.
- 25 13. An antiperspirant product according to any of the preceding claims, characterised by comprising an organic antimicrobial agent.
- 30 14. An antiperspirant product according to any of the preceding claims, characterised by having the antiperspirant salt and the polymer present in independent compositions.

- 32 -

15. An antiperspirant product according to any of claims 1 to 13, characterised by being a composition comprising a non-interacting mixture of the antiperspirant salt and the polymer.
- 5 16. An antiperspirant product according to claim 15, characterised by being an essentially anhydrous composition.
- 10 17. An antiperspirant product according to claim 15 or claim 16, characterised in that the weight ratio of the antiperspirant salt to the polymer is 25:1 or less.
- 15 18. An antiperspirant product according to any of claims 15 to 17, characterised in that the weight ratio of the antiperspirant salt to the polymer is 1:10 or greater.
- 20 19. A cosmetic method of achieving an antiperspirancy and/or deodorancy benefit, said method comprising the topical application to the human body of an antiperspirant product as defined in any of the preceding claims.
- 25 20. A cosmetic method of achieving an antiperspirancy and/or deodorancy benefit, said method comprising bringing together on the surface of the human body an antiperspirant salt and a water soluble polymer comprising Brønsted acid groups which, in the presence of water, acts as a co-gellant for the antiperspirant salt.
- 30 21. A method for the manufacture of an antiperspirant composition according to any of claims 15 to 18, comprising the mixing, in a fluid carrier material, of the antiperspirant salt and the polymer.
- 35

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 June 2002 (27.06.2002)

PCT

(10) International Publication Number  
WO 02/049590 A3

(51) International Patent Classification<sup>7</sup>: A61K 7/32

Port Sunlight, Quarry Road East, Bebington, Wirral,  
Merseyside CH63 3JW (GB).

(21) International Application Number: PCT/EP01/13253

(74) Agents: ELLIOTT, Peter, William et al.; Unilever PLC,  
Patent Dept., Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).

(22) International Filing Date:  
14 November 2001 (14.11.2001)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GA, GE, GN, GQ, GR, GW, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:  
0031264.5 21 December 2000 (21.12.2000) GB

Published:  
— with international search report

(71) Applicant (for AE, AG, AU, BB, BZ, CA, CY, GB, GD, GH, GM, IE, IL, KE, LC, LK, LS, MN, MW, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW only): UNILEVER PLC [GB/GB];  
Unilever House, Blackfriars, London EC4P 4BQ (GB).

(88) Date of publication of the international search report:  
5 December 2002

(71) Applicant (for AL, AM, AT, AZ, BA, BE, BF, BG, BJ, BR, BY, CF, CG, CH, CI, CM, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GA, GE, GN, GQ, GR, GW, HR, HU, ID, IS, IT, JP, KG, KP, KR, KZ, LR, LT, LU, LV, MA, MC, MD, MG, MK, ML, MR, MX, MZ, NE, NL, NO, PH, PL, PT, RO, RU, SE, SI, SK, SN, TD, TG, TJ, TM, TR, UA, UZ, VN, YU only): UNILEVER N.V. [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for IN only): HINDUSTAN LEVER LIMITED [IN/IN]; Hindustan Lever House, 165/166 Backbay Reclamation, Maharashtra, 400 020 Mumbai (IN).

(72) Inventors: SMITH, Ian, Karl; Unilever Research Port Sunlight, Quarry Road East, Bebington, Wirral, Merseyside CH63 3JW (GB). RIELEY, Hugh; Unilever Research

WO 02/049590 A3

(54) Title: ANTIPERSPIRANT PRODUCTS

(57) Abstract: Antiperspirant products and methods for achieving antiperspirancy utilising compositions comprising an antiperspirant salt and a water soluble polymer, characterised in that: i) the polymer comprises Brønsted acid groups and acts as a co-gellant for the antiperspirant salt when mixed therewith in the presence of water; and ii) the polymer is physically separate from antiperspirant salt prior to application.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 01/13253A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K7/32

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 714 551 A (ROHM & HAAS) 1 September 1954 (1954-09-01) Page 2, line 2-8; page 3, lines 29-39; claims 1-14	1-21
A	EP 0 260 030 A (UNILEVER) 16 March 1988 (1988-03-16) page 5, line 16 - line 21; claim 1; example 5	1-21
A	GB 957 175 A (A. FROMONT) 6 May 1964 (1964-05-06) page 1, line 30 - line 53; example 8	1-21
E	US 6 319 491 B1 (M.B. WHIPPLE) 20 November 2001 (2001-11-20) column 3, line 42 - line 55; claims 1-4	1-7 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the International search

6 September 2002

Date of mailing of the International search report

13/09/2002

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax (+31-70) 340-3016

Authorized officer

Willekens, G

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 01/13253

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 640 335 A (BRISTOL-MYERS SQUIBB) 1 March 1995 (1995-03-01) page 9, line 7-18; claims 1-5; example 1	1

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 01/13253

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB 714551	A 01-09-1954	NONE		
EP 260030	A 16-03-1988	AT 81966 T AU 590959 B2 AU 7739487 A BR 8704413 A CA 1296645 A1 DE 3782479 D1 DE 3782479 T2 EP 0260030 A2 ES 2036576 T3 JP 1797943 C JP 5007364 B JP 63068518 A ZA 8706402 A		15-11-1992 23-11-1989 03-03-1988 19-04-1988 03-03-1992 10-12-1992 29-04-1993 16-03-1988 01-06-1993 12-11-1993 28-01-1993 28-03-1988 26-04-1989
GB 957175	A 06-05-1964	FR 1268461 A CH 412202 A		04-08-1961 30-04-1966
US 6319491	B1 20-11-2001	NONE		
EP 640335	A 01-03-1995	US 5393305 A AT 189382 T AU 685136 B2 AU 7145394 A CA 2129491 A1 CN 1105234 A , B DE 69422864 D1 DE 69422864 T2 EP 0640335 A2 JP 7082122 A SG 43865 A1 ZA 9405942 A		28-02-1995 15-02-2000 15-01-1998 09-03-1995 27-02-1995 19-07-1995 09-03-2000 15-06-2000 01-03-1995 28-03-1995 14-11-1997 13-02-1995

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**